Method for detection of, or the risk of, bladder cancer

A bladder cancer, risk technology, applied in the direction of measuring devices, instruments, biomaterial analysis, etc., can solve the lack of accurate diagnosis of bladder cancer sensitivity and specificity of bladder cancer, has not yet reached the high sensitivity of urine cytology, can not correctly evaluate cells exam questions

Inactive Publication Date: 2012-08-01
RANDOX LAB LTD
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, none of the putative biomarkers has yet achieved the high specificity of urine cytology and the high sensitivity of telomerase assays
[0007] Therefore, in the field of bladder cancer diagnosis and treatment, the biomarkers identified in the prior art are unsatisfactory because they lack the sensitivity and specificity required for accurate diagnosis of bladder cancer or assessment of a patient's risk of developing bladder cancer
As a result, clinicians are unable to properly assess whether patients should undergo further cystoscopy and cytology testing, which leads to high costs in diagnosing and managing said disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for detection of, or the risk of, bladder cancer
  • Method for detection of, or the risk of, bladder cancer
  • Method for detection of, or the risk of, bladder cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] A pilot study was performed to determine which individual biomarkers were significantly altered in bladder cancer patients compared with controls, and which variables acted as risk factors for bladder cancer. Seventy-seven patients (55 males; 22 females) were designated as a control group based on negative cystoscopy and absence of symptoms of bladder cancer, followed by additional studies. Their final diagnoses were as follows: no diagnosis (n=36), benign prostatic hyperplasia (BPH) (n=13), stone (n=9), stone with inflammation (n=2), inflammation (n=4), Prostate cancer (n=3), renal cell carcinoma (RCC) (n=2), stone with BPH (n=2), renal cyst (n=1), kidney injury (n=1), urinary tract infection (n=1 =1), fistula (n=1), trauma (n=1), endometriosis (n=1), RCC with BPH (n=1), stone with UTI (n=1) and scaly Stem cell metaplasia (n=1).

[0064] Eighty-two patients (67 males; 15 females) with pathologically proven bladder cancer at the time of sampling were assigned to the T...

Embodiment 2

[0070] Based on the preliminary results of Example 1, further studies were conducted to find specific combinations of biomarkers that could be used to accurately diagnose the presence or risk of bladder cancer in patients without the need for clinical examination Patient exposure to other risk factors was additionally identified during the process. A further study was designed to consider the effect of the multiple risk factors identified in the preliminary study detailed above on the presence of individual biomarkers in samples obtained from patients tested for bladder cancer, making it possible to obtain a panel of specific biomarkers Combinations of specific biomarkers reflect multiple bladder cancer risk factors.

[0071] 181 patients with a history of hematuria were recruited for the bladder cancer trial. Cystoscopy was performed on all patients. Patients assigned to the control group had negative cystoscopy or subsequent normal pathology, while patients assigned to the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a method for the detection of, or the risk of, bladder cancer in a patient, comprising the step of detecting the presence of a combination of at least two biomarkers selected from CEA, VEGF, IL-8, NGAL, NSE, IL-2, EGF, TM, d-Dimer, MMP-9, IL-6, IL-4, MMP-9 / NGAL, FAS, CRP, TUP and NMP22 in one or more samples isolated from a patient wherein the presence of a combination of at least two biomarkers in the one or more samples indicates the presence or risk of bladder cancer.

Description

technical field [0001] The present invention relates to methods of detecting the presence or risk of bladder cancer in a patient. Background technique [0002] Bladder cancer is one of the leading causes of death worldwide. Bladder cancer is more than three times as common in men as in women, but the death rate in women is twice that of men. Most patients with superficial bladder cancer tumors will relapse within 5 years, and almost 90% of these patients will relapse within 15 years. Therefore, it is crucial to follow up these patients regularly to ensure that the cancer has not spread outside the bladder. Continuous surveillance and expensive diagnostic techniques make bladder cancer the most expensive cancer from diagnosis to death on a per patient basis. [0003] The effectiveness of a diagnostic test is measured by its sensitivity and specificity. Test sensitivity is the number of true positives (number of individuals with the disease who test positive for a particul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/57407G01N2800/34
Inventor M·W·拉德克C·N·里德K·威廉森J·V·拉蒙特S·P·菲茨杰拉德
Owner RANDOX LAB LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap